{"prompt": "['LIST OF ABBREVIATIONS AND TERMS', 'List of Abbreviations', 'Abbreviation', 'Term', 'AE', 'Adverse Event', 'ASV', 'Accessory Saphenous Vein', 'CEAP', 'Clinical-Etiology-Anatomy-Pathophysiology Classification', 'DICOM', 'Digital Imaging and Communications in Medicine', 'DVT', 'Deep Venous Thrombosis', 'EO', 'Ethylene Oxide', 'EQ-5D-5L', 'European Quality of Life - 5 Dimensions', 'FDA', 'Food and Drug Administration (United States of America)', 'GCP', 'Good Clinical Practice', 'GSV', 'Great Saphenous Vein', 'HASTI', 'Heaviness, Achiness, Swelling, Throbbing, Itching', 'IC', 'Intravascular Coagulation', 'IRB', 'Institutional Review Board', 'MDU', 'Motor Drive Unit', 'PASTE', 'Post-Ablation Superficial Thrombus Extension', 'PE', 'Pulmonary Embolism', 'rVCSS', 'Revised Venous Clinical Severity Score', 'SAE', 'Serious Adverse Event', 'SFJ', 'Sapheno-Femoral Junction or Saphenofemoral Junction', 'SSV', 'Small Saphenous Vein', 'STS', 'Sodium Tetradecyl Sulfate', 'SVS', 'Saphenous Vein Segment', 'TS', 'Treatment Section', 'US', 'United States', 'VAS', 'Visual Analog Scale', 'VEINES-QOL/SYM', 'Venous Insufficiency Epidemiological and Economic Study-Quality of', 'Life Questionnaire', 'VI', 'Vascular Insights, LLC', 'Page 14 of 101']['List of Terms and Definitions', 'Term', 'Definition', 'Adverse Event', 'An adverse event (AE) is any untoward medical occurrence in a patient or', 'clinical investigation subject administered a study product. The occurrence,', 'which may or may not have a causal relationship with the investigational', 'treatment, may include any clinical or laboratory change that does not', 'commonly occur in that patient and is considered clinically significant.', 'Baseline', 'Establishment of patient eligibility for study treatment at least 7 days prior to', 'Treatment visit (Visit 2)', 'CEAP Classification', 'The CEAP classification is a method for evaluating venous disease of the leg', 'based on clinical, etiologic, anatomic, and pathophysiologic data.', 'CRO', 'Clinical Research Organization, which may be assigned responsibility to', 'perform selected function of the study', 'Day-of-Treatment', 'The day on which the single-treatment procedure is performed- the', 'treatment begins and ends on the same day (Visit 3)', 'End-of-Study for Patient', 'The end of study for a patient is when the patient has completed the required', 'post-treatment study visits or has discontinued from the study.', 'Enrolled Patient', 'Individual who has signed the Informed Consent Form.', 'Elimination of Saphenous Vein', 'Vein closure and/or vein competence of the treatment section (TS) of the', 'Reflux', 'selected saphenous vein, as demonstrated by duplex ultrasound at Week 12', 'post treatment (Visit 6)', 'Follow-up Period', 'From the day following Day of Treatment (Visit 3) to completion of the', 'Week 1, 6 and 12 (Visits 4, 5 and 6) post-treatment follow-up visits', 'HASTI', 'Heaviness, Achiness, Swelling, Throbbing, Itching symptom from VEINES-', 'QOL/Sym questionnaire', 'Institutional Review Board', 'A type of committee used in research in the United States that has been', '(IRB)', 'formally designated to approve, monitor, and review biomedical and', 'behavioral research involving humans', 'Regulatory Agency', 'USA Food and Drug Administration (FDA)', 'Saphenous Vein Segment', 'A segment of saphenous vein with no deep venous junction', 'Screening Period', 'After reviewing and signing the Informed Consent Form (ICF) for', 'participation in the study, an individual will be screened for eligibility to', 'participate in study during Screening (Visit 1), Baseline (Visit 2), Day of', 'Treatment (Visit 3).', 'Sponsor', 'Vascular Insights, LLC', 'Page 15 of 101']['Term', 'Definition', 'Start-of-Study', 'Study starts when first patient signs the ICF (Visit 1).', 'Study Drug', 'Sodium Tetradecyl Sulfate (STS) 1% and 3%', 'Study Drug Delivery System', 'ClariVein infusion catheter system', 'Study Product', 'ClariVein RES (Sodium Tetradecyl Sulfate delivered via the ClariVein', 'infusion catheter system)', 'VICARES Clinical Study', 'A manual provided to the Investigational Sites that include instruction for', 'Procedure Manual', 'device operation, study drug and delivery device preparation, and ultrasound', 'assessments for the ClariVein RES.', 'Study Treatment', 'The study treatment, is the endovenous administration of either 1% or 3%', 'STS delivered intravenously via the ClariVein, with a maximum STS', 'volume of 10 mL per single treatment procedure.', 'Suspected Adverse Event', 'Any adverse event (AE) for which there is a reasonable possibility that the', 'study product caused the AE. For the purposes of IND safety reporting,', '\"reasonable possibility\" means there is evidence to suggest a causal', 'relationship between the investigational product and the AE.', 'Treatment Section', 'The treatment section (TS) is the portion of the selected saphenous vein to be', 'treated with ClariVein RES.', 'Treatment Section Length', 'The treatment section length (TSL) is the portion of the selected saphenous', 'vein to be treated with ClariVein RES.', 'Treatment Section Diameter', 'The average diameter of the treatment section (TS).', 'Vein Closure', 'No discrete open section of vein >5 cm in length within the treatment section', '(TS) of the selected saphenous vein, as assessed by duplex ultrasound.', 'Vein Competence', 'Absence of retrograde flow >500ms (0.5s) within the treatment section (TS)', 'of the selected saphenous vein, as assessed by duplex ultrasound.', 'Page 16 of 101']\n\n###\n\n", "completion": "END"}